HOME >> MEDICINE >> NEWS
Pfizer's VFEND(R) receives FDA approval for treatment of esophageal candidiasis

NEW YORK, November 17, 2003 - Pfizer Inc said today that it has received U.S. Food and Drug Administration (FDA) approval to market VFEND (voriconazole), a broad spectrum antifungal medicine, for the treatment of esophageal candidiasis.

Candida organisms are normally found on skin and mucous membranes in healthy individuals, but in persons whose immune systems are weakened or compromised by cancer chemotherapy, organ transplants or HIV/AIDS, Candida can multiply causing potentially serious infections. In immunocompromised patients, esophageal candidiasis may coat much of the surface of the mouth resulting in pain and difficulty swallowing and may ultimately progress to more serious, invasive disease.

The basis for the approval of VFEND to treat esophageal candidiasis infections was a clinical trial with immunocompromised patients conducted at study sites in 15 countries. All patients had a proven diagnosis of esophageal candidiasis and most of the patients also had additional underlying diseases, such as hematologic malignancies, chronic obstructive pulmonary disease (COPD) and AIDS.

Patients received either VFEND or fluconazole. Those treated with VFEND had success rates of 98 percent compared to 95 percent for fluconazole. Both VFEND and fluconazole had acceptable tolerability and safety. VFEND was discovered by Pfizer researchers and was developed to address the unmet medical need for more effective and better-tolerated options for patients with invasive aspergillosis and other serious fungal infections.

Initially, VFEND was approved in the U.S. for the primary treatment of acute invasive aspergillosis and salvage therapy for rare but serious fungal infections caused by the pathogens Scedosporium apiospermum and Fusarium spp. VFEND can be administered both orally and intravenously. Pfizer is continuing to study VFEND for the treatment of serious fungal infections.

In clinical trials, the most common adverse
'"/>

Contact: Susan Yarin
susan.yarin@pfizer.com
212-733-5260
Edelman Public Relations
17-Nov-2003


Page: 1 2

Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. Pfizers antifungal medicine VFEND receives FDA approval
3. New data sets survival benchmark for Pfizers ELLENCE
4. Pfizers VFEND (R) as effective in treating Candidemia as two-drug standard of care, study shows
5. Pfizers ZYVOX(TM) more effective than vancomycin in treating complicated SSTIs caused by MRSA
6. UIC professor receives international humanitarian award
7. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
8. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
9. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
10. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
11. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 13, 2017 , ... ProVest Insurance Group, a family managed ... Raleigh regions, is organizing an extended charity drive to benefit the family of ... , After struggling since birth with several health challenges, T.J. was later diagnosed ...
(Date:10/13/2017)... PITTSBURGH, Pa. (PRWEB) , ... October 13, 2017 , ... ... the dark poses a problem. Fortunately, an inventor from Austin, Texas, has identified a ... access to medication in darkness or restricted lighting. As such, it eliminates the need ...
(Date:10/13/2017)... ... 2017 , ... PurhealthRX , a leading Health and Nutrition Company, is ... to full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing ... easily incorporated into liquid products, while reducing costs to end users. , The team ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Apple Rehab ... services, staged a mock evacuation of the facility as part of a disaster drill ... Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
Breaking Medicine Technology:
Cached News: